ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,108,341 | -21.5% | 115,241 | +2.7% | 1.22% | +10.7% |
| Q2 2023 | $5,236,042 | +17.9% | 112,241 | +1.4% | 1.10% | -26.0% |
| Q1 2023 | $4,440,714 | -7.9% | 110,741 | +3.7% | 1.49% | -18.4% |
| Q4 2022 | $4,821,491 | +44.4% | 106,741 | +29.6% | 1.83% | +50.7% |
| Q3 2022 | $3,339,000 | -46.6% | 82,341 | -21.5% | 1.21% | -41.5% |
| Q2 2022 | $6,258,000 | -23.6% | 104,899 | -6.9% | 2.07% | +14.6% |
| Q1 2022 | $8,186,000 | -4.6% | 112,727 | +10.7% | 1.81% | +6.4% |
| Q4 2021 | $8,579,000 | – | 101,831 | – | 1.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |